KR20240021833A - 유전성 혈색소 침착증의 치료를 위한 헵시딘 모방체 - Google Patents

유전성 혈색소 침착증의 치료를 위한 헵시딘 모방체 Download PDF

Info

Publication number
KR20240021833A
KR20240021833A KR1020237044819A KR20237044819A KR20240021833A KR 20240021833 A KR20240021833 A KR 20240021833A KR 1020237044819 A KR1020237044819 A KR 1020237044819A KR 20237044819 A KR20237044819 A KR 20237044819A KR 20240021833 A KR20240021833 A KR 20240021833A
Authority
KR
South Korea
Prior art keywords
seq
compound
peptide
isovaleric acid
palm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237044819A
Other languages
English (en)
Korean (ko)
Inventor
수닐 쿠마르 굽타
데이비드 와이. 리우
니쉬트 바추랄 모디
프랭크 호레이스 발론
Original Assignee
프로타고니스트 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로타고니스트 테라퓨틱스, 인코포레이티드 filed Critical 프로타고니스트 테라퓨틱스, 인코포레이티드
Publication of KR20240021833A publication Critical patent/KR20240021833A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
KR1020237044819A 2021-06-14 2022-06-14 유전성 혈색소 침착증의 치료를 위한 헵시딘 모방체 Pending KR20240021833A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163210453P 2021-06-14 2021-06-14
US63/210,453 2021-06-14
US202163252001P 2021-10-04 2021-10-04
US63/252,001 2021-10-04
US202263349841P 2022-06-07 2022-06-07
US63/349,841 2022-06-07
PCT/US2022/033378 WO2022266060A1 (en) 2021-06-14 2022-06-14 Hepcidin mimetics for treatment of hereditary hemochromatosis

Publications (1)

Publication Number Publication Date
KR20240021833A true KR20240021833A (ko) 2024-02-19

Family

ID=84527344

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237044819A Pending KR20240021833A (ko) 2021-06-14 2022-06-14 유전성 혈색소 침착증의 치료를 위한 헵시딘 모방체

Country Status (11)

Country Link
US (1) US20240293511A1 (https=)
EP (2) EP4355763A4 (https=)
JP (1) JP2024520861A (https=)
KR (1) KR20240021833A (https=)
AU (1) AU2022293672A1 (https=)
BR (1) BR112023026381A2 (https=)
CA (1) CA3220871A1 (https=)
IL (1) IL309166A (https=)
MX (1) MX2023015021A (https=)
TW (1) TW202317604A (https=)
WO (1) WO2022266060A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3167751A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7397239B2 (ja) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ．ベー． インターロイキン－２３受容体のペプチド阻害剤の組成物
EP4370146A4 (en) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidated peptide inhibitors of the interleukin-23 receptor
WO2025207760A1 (en) * 2024-03-27 2025-10-02 Protagonist Therapeutics, Inc. Formulations of a hepcidin peptide analogue

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) * 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
WO2015200916A2 (en) * 2014-06-27 2015-12-30 Protagonist Therapeutics, Inc. Hepcidin and mini-hepcidin analogues and uses therof
EP3240799B1 (en) * 2014-12-29 2021-03-31 The Regents of the University of California S-alkylated hepcidin peptides and methods of making and using thereof
US20190002503A1 (en) * 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
PH12022550510A1 (en) * 2019-09-03 2023-09-04 Protagonist Therapeutics Inc Conjugated hepcidin mimetics

Also Published As

Publication number Publication date
IL309166A (en) 2024-02-01
JP2024520861A (ja) 2024-05-24
EP4737477A2 (en) 2026-05-06
US20240293511A1 (en) 2024-09-05
EP4355763A1 (en) 2024-04-24
AU2022293672A9 (en) 2024-01-11
AU2022293672A1 (en) 2023-12-14
TW202317604A (zh) 2023-05-01
BR112023026381A2 (pt) 2024-03-05
WO2022266060A1 (en) 2022-12-22
CA3220871A1 (en) 2022-12-22
EP4355763A4 (en) 2025-07-30
MX2023015021A (es) 2024-01-26

Similar Documents

Publication Publication Date Title
KR20240021833A (ko) 유전성 혈색소 침착증의 치료를 위한 헵시딘 모방체
US12269856B2 (en) Hepcidin analogues and uses thereof
EP4025592B1 (en) Conjugated hepcidin mimetics for use in treating of polycythemia vera
KR20170043509A (ko) 헵시딘 및 미니-헵시딘 유사체 및 그의 용도
KR20230053615A (ko) 접합된 헵시딘 모방체
WO2017117411A1 (en) Analogues of hepcidin mimetics with improved in vivo half lives
US20250360187A1 (en) Hepcidin mimetics for treatment of sickle cell disease
WO2024011188A1 (en) Combination therapy for treatment of iron overload diseases
CN117480176A (zh) 用于治疗遗传性血色病的铁调素模拟物
HK40084564A (en) Hepcidin analogues and uses thereof
EA048412B1 (ru) Конъюгированные миметики гепсидина
HK1220112B (en) Hepcidin analogues and uses therof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231226

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250612

Comment text: Request for Examination of Application